Brief: Heidelberg Pharma FY EPS Loss Widens To EUR 0.61

Heidelberg Pharma AG

25/03/2021 06:17

March 25 (Reuters) - HEIDELBERG PHARMA AG  HPHA.DE :
    * FY REVENUE 8.5 MILLION EUR VERSUS 7.3 MILLION EUR YEAR AGO
    * FY EPS LOSS 0.61 EUR VERSUS 0.36 EUR LOSS YEAR AGO
    * FY OTHER INCOME OF EUR 1.1 MILLION (PREVIOUS YEAR: EUR 0.7
MILLION)
    * IN FISCAL YEAR 2020, HEIDELBERG PHARMA GROUP GENERATED
SALES
REVENUE OF EUR 8.5 MILLION (PREVIOUS YEAR: EUR 7.3 MILLION)
    * EARNINGS BEFORE INTEREST AND TAXES (EBIT) FOR 2020 ARE
EXPECTED
TO BE BETWEEN EUR -30.0 MILLION AND EUR -34.0 MILLION (2020: EUR
-18.3 MILLION).
    * GROUP'S FINANCING IS SECURED UNTIL MID-2022 BASED ON
CURRENT
PLANNING.
    * OUTLOOK 2021: FUNDING REQUIREMENT EXPECTED TO INCREASE
COMPARED
WITH 2020 AND SHOULD RANGE BETWEEN EUR 30.0 MILLION AND EUR 34.0
MILLION
    * EXPECTS TO GENERATE BETWEEN EUR 5.5 MILLION AND EUR 7.5
MILLION
IN SALES REVENUE AND OTHER INCOME (2020: EUR 9.6 MILLION) FOR
2021 FISCAL YEAR

Source text for Eikon:  ID:nEQ9kvyKCa 
Further company coverage:  HPHA.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))